Cytosorbents Corporation (NASDAQ:CTSO) has been given a $12.00 target price by investment analysts at Maxim Group in a research report issued to clients and investors on Thursday. The brokerage currently has a “buy” rating on the medical research company’s stock. Maxim Group’s target price would suggest a potential upside of 98.35% from the company’s current price.

Several other equities research analysts have also recently commented on CTSO. Aegis reissued a “buy” rating and set a $9.00 target price on shares of Cytosorbents Corporation in a report on Tuesday, July 25th. B. Riley reissued a “buy” rating and set a $11.25 target price on shares of Cytosorbents Corporation in a report on Wednesday, August 2nd. HC Wainwright set a $13.00 target price on Cytosorbents Corporation and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, ValuEngine raised Cytosorbents Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Cytosorbents Corporation currently has a consensus rating of “Buy” and an average target price of $10.45.

Shares of Cytosorbents Corporation (CTSO) opened at 6.05 on Thursday. The firm’s market cap is $170.20 million. Cytosorbents Corporation has a 12-month low of $3.30 and a 12-month high of $6.70. The company has a 50 day moving average price of $5.88 and a 200-day moving average price of $4.90.

Cytosorbents Corporation (NASDAQ:CTSO) last announced its earnings results on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. The firm had revenue of $3.57 million for the quarter, compared to analysts’ expectations of $3.29 million. Analysts expect that Cytosorbents Corporation will post ($0.27) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at

A hedge fund recently raised its stake in Cytosorbents Corporation stock. Skylands Capital LLC increased its position in shares of Cytosorbents Corporation (NASDAQ:CTSO) by 87.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 594,250 shares of the medical research company’s stock after purchasing an additional 277,650 shares during the period. Skylands Capital LLC owned 2.11% of Cytosorbents Corporation worth $2,555,000 at the end of the most recent quarter. 6.89% of the stock is currently owned by institutional investors.

About Cytosorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents Corporation (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.